Interim report January - September 2013

High growth and improved income

Third quarter:

Continuing operations

  • Sales growth was 33 percent in local currency. Sales amounted to SEK 109 (83) million, corresponding to an increase of 31 percent in SEK.
  • Operating income (EBIT) amounted to SEK 23 (15) million, corresponding to an operating margin of 21 (18) percent.
  • The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated.
  • Net income amounted to SEK 17 (9) million, which gave earnings per share of SEK 0.85 (0.45).
  • Agreement with Xvivo Perfusion AB to terminate contract manufacturing of STEEN Solution™ during the fourth quarter of 2013.

January - September:

Continuing operations

  • Sales growth was 30 percent in local currency. Sales amounted to SEK 329 (264) million, corresponding to an increase of 25 percent in SEK.
  • Operating income (EBIT) amounted to SEK 59 (38) million, corresponding to an operating margin of 18 (14) percent.
  • The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated.
  • Net income amounted to SEK 41 (27) million, which gave earnings per share of SEK 2.06 (1.36).

Gothenburg, November 7, 2013

VITROLIFE AB (publ)

Thomas Axelsson, CEO

Report

Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 7, 2013 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.